News

Biopharma Has ‘Trials Progressing; Multiple 2022 Data Readouts’ Including for PTSD

May 20, 2021 (Investorideas.com Newswire) Updates on Aptinyx’s three central nervous system drug candidates and the company’s Q1/21 earnings are delivered in an H.C. Wainwright & Co. report.

What's your reaction?

Excited
0
Happy
0
In Love
0
Not Sure
0
Silly
0

You may also like

Leave a reply

Your email address will not be published. Required fields are marked *

More in:News

News

Following the minerals

September 17, 2021 (Investorideas.com Newswire) “Nature abhors a vacuum” is a familiar maxim in science. ...